Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Congenital Hyperinsulinism: early-phase trial registry
3 of 8 indexed Congenital Hyperinsulinism trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Congenital Hyperinsulinism: 8 US clinical trials tracked, 3 recruiting.
Congenital Hyperinsulinism is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Zealand Pharma, running 2 of these trials.
Enrollment posture brief
Registry condition congenital-hyperinsulinism
OPEN 3 | RECR 38% | LATE 2 | EARLY 6 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
Congenital Hyperinsulinism lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Congenital Hyperinsulinism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Congenital Hyperinsulinism is recruiting below its size-band peers.
3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Congenital Hyperinsulinism research.
Zealand Pharma accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Congenital Hyperinsulinism trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.
-
Congenital Hyperinsulinism research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
Cook Children's Health Care System
NCT02021604
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
Miguel Pampaloni
NCT04205604
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
Hanmi Pharmaceutical Company Limited
NCT04732416
RZ358 Treatment for Congenital Hyperinsulinism
Rezolute
NCT06208215
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Zealand Pharma
NCT03941236
Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
Children's Hospital of Philadelphia
NCT00674440
Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity
Diva De Leon
NCT00897676
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Zealand Pharma
NCT04172441
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Congenital Hyperinsulinism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Congenital Hyperinsulinism trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Congenital Hyperinsulinism page
8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Congenital Hyperinsulinism trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Zealand Pharma sponsors the most Congenital Hyperinsulinism trials on record, review their full trial history before evaluating a specific study. See Zealand Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Congenital Hyperinsulinism condition card totals 8 registered trials; most-linked intervention dasiglucagon; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.